Warning letter
Algunas Inc., dba Woodland Hills Compounding Pharmacy: warning letter of Jul 17, 2017
FDA warning letter 532739 · Los Angeles District Office
Key facts
| Reference number | 532739 |
|---|---|
| Company | Algunas Inc., dba Woodland Hills Compounding Pharmacy |
| Subject | Unapproved New Drug/Compounding/Misbranding/Adulterated |
| Issue date | Jul 17, 2017 |
| Posted date | Jul 17, 2017 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 201.115, 211.192, 211.42(c) |
| Inspection city | Woodland Hills |
| Inspection ZIP | 91364 |
| Inspection start date | Apr 25, 2016 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: